ATE445395T1 - Verfahren zur unterdrückung der ptx3 genexpression - Google Patents

Verfahren zur unterdrückung der ptx3 genexpression

Info

Publication number
ATE445395T1
ATE445395T1 AT03746454T AT03746454T ATE445395T1 AT E445395 T1 ATE445395 T1 AT E445395T1 AT 03746454 T AT03746454 T AT 03746454T AT 03746454 T AT03746454 T AT 03746454T AT E445395 T1 ATE445395 T1 AT E445395T1
Authority
AT
Austria
Prior art keywords
sup
sub
suppressing
gene expression
ptx
Prior art date
Application number
AT03746454T
Other languages
German (de)
English (en)
Inventor
Shigeru Morikawa
Akashi Izumi
Takao Hamakubo
Tatsuhiko Kodama
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Application granted granted Critical
Publication of ATE445395T1 publication Critical patent/ATE445395T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03746454T 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression ATE445395T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37211402P 2002-04-15 2002-04-15
US10/196,428 US20030195167A1 (en) 2002-04-15 2002-07-17 PTX3-gene expression inhibitor
PCT/JP2003/004603 WO2003086380A1 (en) 2002-04-15 2003-04-11 Ptx3 gene expression suppressing method

Publications (1)

Publication Number Publication Date
ATE445395T1 true ATE445395T1 (de) 2009-10-15

Family

ID=28794074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746454T ATE445395T1 (de) 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression

Country Status (9)

Country Link
US (2) US20030195167A1 (https=)
EP (1) EP1494661B1 (https=)
JP (1) JP4409295B2 (https=)
AT (1) ATE445395T1 (https=)
AU (1) AU2003226456A1 (https=)
DE (1) DE60329668D1 (https=)
MY (1) MY137134A (https=)
TW (1) TWI349547B (https=)
WO (1) WO2003086380A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤
WO2005053683A1 (en) 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
WO2005080981A1 (ja) * 2004-02-25 2005-09-01 Perseus Proteomics Inc. 血管障害の程度の判定方法
ES2311986T3 (es) * 2004-04-26 2009-02-16 Alcon, Inc. Estatinas para el tratamiento de la hipertension ocular y del glaucoma.
US20090203701A1 (en) * 2006-06-29 2009-08-13 Kowa Co., Ltd Prophylactic and/or therapeutic agent for rheumatoid arthritis
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
EP1163203A1 (en) * 1999-03-08 2001-12-19 Merck & Co., Inc. Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
WO2001058443A1 (fr) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. INHIBITEURS DE TNF-$g(a)
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent

Also Published As

Publication number Publication date
AU2003226456A8 (en) 2003-10-27
EP1494661B1 (en) 2009-10-14
JP2005522490A (ja) 2005-07-28
TW200403990A (en) 2004-03-16
WO2003086380A1 (en) 2003-10-23
EP1494661A1 (en) 2005-01-12
AU2003226456A1 (en) 2003-10-27
US20080161348A1 (en) 2008-07-03
US20030195167A1 (en) 2003-10-16
JP4409295B2 (ja) 2010-02-03
DE60329668D1 (de) 2009-11-26
MY137134A (en) 2008-12-31
TWI349547B (en) 2011-10-01

Similar Documents

Publication Publication Date Title
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
EA200600358A1 (ru) Фенил- или пиридиламидные соединения в качестве антагонистов простагландина е2
NO20055337L (no) Imidazolinkorrosjonsinhibitorer
ATE349435T1 (de) Dpiv-inhibitoren auf glutaminbasis
MY142807A (en) Benzimidazole derivative and use thereof.
EP1063228A4 (en) CYCLOALCENE DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
ATE402185T1 (de) Verfahren für fluorcytidinderivate
ATE445395T1 (de) Verfahren zur unterdrückung der ptx3 genexpression
ATE207055T1 (de) Verfahren zur herstellung von 4-aryl-3- hydroxymethyl-piperidinen
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
ATE428693T1 (de) Prostaglandinsynthese
YU45582B (sh) Postopek za pripravo derivatov arilamina
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
DE60140333D1 (de) Lichtempfindliche Verbindung und lichtempfindliches Harz
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
MXPA05013981A (es) Resolucion de derivados de acido a- (fenoxi) fenilacetico.
EA200100065A1 (ru) Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf
GB0316268D0 (en) Process for preparing cyclic organohydrogensiloxanes
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
FR2826005B1 (fr) Synthese totale de la galanthamine, de ses analogues et de ses derives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties